Inclusion Criteria:

1. Patients must have signed an approved informed consent.

2. Histologically confirmed progressive or recurrent endometrial cancer (endometrioid,
serous, clear cell, mixed malignant Mullerian tumors, or mixed histology; any grade).

3. Patients must have failed at least one prior chemotherapeutic regimen for recurrent
disease (does not include chemosensitizing radiation).

4. All patients must have measurable disease. Measurable disease is defined as lesions
that can be accurately measured in at least one dimension (longest dimension to be
recorded). Each lesion must be > 20 mm when measured by conventional techniques,
including palpation, plain x-ray, CT, and MRI, or > 10 mm when measured by spiral CT.
Ascites and pleural effusions are not considered measurable disease. If the
measurable disease is restricted to a solitary lesion, its neoplastic nature should
be confirmed by cytology/histology.

5. Patients must have a Zubrod performance status of 0, 1, or 2.

6. Patients must either be not of child bearing potential or have a negative pregnancy
test within 7 days of treatment. Patients are considered not of child bearing
potential if they are surgically sterile (they have undergone a hysterectomy,
bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal for
greater than 12 months.

7. Patients must have a pretreatment granulocyte count (i.e., segmented neutrophils +
bands) of >1,000/Fl, a hemoglobin level of >/= 9.0 gm/dL and a platelet count of
>75,000/Fl.

8. Patients must have an adequate renal function as documented by serum creatinine 2.0 mg/dL.

9. Patients must have adequate hepatic function as documented by a serum bilirubin 2.5 mg/dL, regardless of whether patients have liver involvement secondary to tumor.

10. Aspartate transaminase (SGOT) must be unless the liver is involved with tumor, in that case, the aspartate transaminase
must be
11. Prior to beginning therapy, at least 4 weeks must have elapsed since prior
chemotherapy, surgery, radiation therapy or investigational therapy. Patients
receiving palliative radiation therapy are exempt from the 4 week waiting period.

Exclusion Criteria:

1. Patients who have uterine sarcomas.

2. Patients who have isolated recurrences (vaginal, pelvic, or paraaortic) that are
amenable to potentially curative treatment with radiation therapy or surgery.

3. Patients with any other severe concurrent disease, which would make the patient
inappropriate for entry into this study, including significant hepatic, renal, or
gastrointestinal diseases.

4. Patients with a history of prior malignancy except for adequately treated basal cell
or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the
patient has been disease-free for at least five years.

5. Patients with active or uncontrolled systemic infection.

6. Patients with history of uncontrolled cardiac disease; i.e., uncontrolled
hypertension, unstable angina, recent myocardial infarction (within prior 6 months),
uncontrolled congestive heart failure, and cardiomyopathy with an ejection fraction
under 40%.

7. Patients who received prior therapy that specifically and directly targets the EGFR
pathway.

8. Patients who experienced prior severe infusion reaction to a monoclonal antibody.

9. Patients who are pregnant or breast feeding.

10. Presence of clinically apparent untreated central nervous system metastases.

11. Patients with carcinomatous meningitis.

12. Patients with deep venous or arterial thrombosis (including pulmonary embolism)
within 6 weeks of study entry. Patients may be on maintenance anticoagulation
therapy.

13. Patients with previously documented human immunodeficiency virus (HIV) infection.

14. Patients currently receiving chemotherapy or radiation therapy.